Read: Springer to acquire BioMed Central Group from Springer's News postings (written 7 October 2008).
So, Springer, a big commercial name in STM (Science, technology, medicine) publishing has bought the biggest open access (OA) STM publisher so far. Woah. That just sounds wrong. Or very, very good, depending on how you look at it. Worst case scenario: Springer's commercial, for-profit perspective run's BioMed Central into the ground, destroying one of OA's big success stories. Best case: Both flourish and OA is shown to be viable for commercial publishers to embrace, and everyone everywhere is convinced, and we all live happily ever after.
Don't know where in the middle it will fall... Any ideas?